Chordoma Foundation,
Phase II trial shows that 22% of patients with advanced EGFR positive chordoma benefitted from Lapatinib (Tykerb), a drug…
Phase II study on lapatinib in advanced EGFR-positive chordoma †
Overview of attention for article published in Annals of Oncology, April 2013
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (80th percentile)
-
Good Attention Score compared to outputs of the same age and source (72nd percentile)
Mentioned by
- 3 X users
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- f1000
- 1 research highlight platform
Readers on
- mendeley
- 80 Mendeley